Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1807 2
1820 1
1827 1
1828 1
1880 1
1884 4
1885 4
1886 3
1887 1
1888 3
1889 1
1890 5
1892 5
1893 6
1894 2
1905 1
1911 1
1914 1
1917 1
1920 1
1927 2
1928 2
1930 6
1931 2
1933 2
1934 2
1935 2
1940 1
1941 1
1942 1
1944 4
1945 2
1946 14
1947 6
1948 8
1949 11
1950 8
1951 15
1952 13
1953 19
1954 19
1955 11
1956 18
1957 23
1958 19
1959 33
1960 28
1961 21
1962 18
1963 17
1964 31
1965 38
1966 21
1967 27
1968 29
1969 40
1970 42
1971 29
1972 49
1973 45
1974 29
1975 31
1976 47
1977 34
1978 46
1979 43
1980 49
1981 45
1982 54
1983 53
1984 63
1985 52
1986 76
1987 67
1988 72
1989 69
1990 82
1991 95
1992 95
1993 80
1994 99
1995 91
1996 85
1997 102
1998 114
1999 112
2000 122
2001 109
2002 132
2003 149
2004 153
2005 164
2006 193
2007 159
2008 201
2009 214
2010 211
2011 237
2012 256
2013 281
2014 268
2015 319
2016 357
2017 318
2018 323
2019 348
2020 394
2021 436
2022 381
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

7,573 results
Results by year
Filters applied: . Clear all
Page 1
Age-Related Macular Degeneration.
Thomas CJ, Mirza RG, Gill MK. Thomas CJ, et al. Med Clin North Am. 2021 May;105(3):473-491. doi: 10.1016/j.mcna.2021.01.003. Epub 2021 Apr 2. Med Clin North Am. 2021. PMID: 33926642 Free article. Review.
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kong S, Lee A, Coleman S, Zou W, McCleland M, Shankar G, Reck M. Socinski MA, et al. Among authors: thomas ca. J Thorac Oncol. 2021 Nov;16(11):1909-1924. doi: 10.1016/j.jtho.2021.07.009. Epub 2021 Jul 24. J Thorac Oncol. 2021. PMID: 34311108 Free article.
Oncologic emergencies and urgencies: A comprehensive review.
Gould Rothberg BE, Quest TE, Yeung SJ, Pelosof LC, Gerber DE, Seltzer JA, Bischof JJ, Thomas CR Jr, Akhter N, Mamtani M, Stutman RE, Baugh CW, Anantharaman V, Pettit NR, Klotz AD, Gibbs MA, Kyriacou DN. Gould Rothberg BE, et al. Among authors: thomas cr jr. CA Cancer J Clin. 2022 Nov;72(6):570-593. doi: 10.3322/caac.21727. Epub 2022 Jun 2. CA Cancer J Clin. 2022. PMID: 35653456 Free article. Review.
Contemporary radiotherapy: present and future.
Chandra RA, Keane FK, Voncken FEM, Thomas CR Jr. Chandra RA, et al. Among authors: thomas cr jr. Lancet. 2021 Jul 10;398(10295):171-184. doi: 10.1016/S0140-6736(21)00233-6. Epub 2021 Jun 21. Lancet. 2021. PMID: 34166607 Review.
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. Nogami N, et al. Among authors: thomas ca. J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7. J Thorac Oncol. 2022. PMID: 34626838 Clinical Trial.
Postmortem investigation of fatalities following vaccination with COVID-19 vaccines.
Schneider J, Sottmann L, Greinacher A, Hagen M, Kasper HU, Kuhnen C, Schlepper S, Schmidt S, Schulz R, Thiele T, Thomas C, Schmeling A. Schneider J, et al. Among authors: thomas c. Int J Legal Med. 2021 Nov;135(6):2335-2345. doi: 10.1007/s00414-021-02706-9. Epub 2021 Sep 30. Int J Legal Med. 2021. PMID: 34591186 Free PMC article.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Attard G, et al. Among authors: thomas c. Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23. Lancet. 2022. PMID: 34953525 Free PMC article.
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Shaffer AL 3rd, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Häupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Sun C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM. Shaffer AL 3rd, et al. Among authors: thomas cj. Blood Cancer Discov. 2021 Sep 14;2(6):630-647. doi: 10.1158/2643-3230.BCD-21-0063. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778802 Free PMC article.
7,573 results